TaiGen Biotechnology Co. Ltd., of Taipei, Taiwan, said Warner Chilcott plc, of Ardee, Ireland, will transfer the worldwide rights for nemonoxacin, a nonfluorinated quinolone antibiotic in development for antibiotic-resistant infections, to TaiGen, giving the biotech worldwide rights to the drug.